• ClearOne agreed to acquire Vivani Medical’s Cortigent unit via a merger, leaving Cortigent as a wholly owned subsidiary at closing.
• Vivani will receive 12,500,000 ClearOne shares; it is expected to own 59.4%-67.5% of the combined company.
• Legacy ClearOne shareholders are expected to hold 12.7%-14.4% following the deal and a concurrent equity financing.
• ClearOne plans to file a Form S-1 to raise $10 million-$15 million alongside the closing.
• The combined company is expected to close in Q3 2026, rebrand as Cortigent Holdings, and trade under Nasdaq ticker CRGT.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearOne Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001753926-26-001137), on July 06, 2026, and is solely responsible for the information contained therein.